Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

Cancer

Volumn 115, Issue 1, 2009, Pages 61-67

  Dudek, Arkadiusz Z ^a,d   Zolnierek, Jakub ^b   Dham, Anu ^a   Lindgren, Bruce R ^c   Szczylik, Cezary ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib; Tyrosine kinase inhibition

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IC 50; KIDNEY CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; VOMITING; CANCER CONTROL; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; RASH; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 58949092548     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24009     Document Type: Article

References (13)

1. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
2. Motzer RJ, Hutson TE, Tomczack P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
3. Wilhelm S, Carter C, Tang L, et al. BAY-43-9006 exhibits broad oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
4. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
5. Szczylik C, Demkow T, Staehler M, et al. Randomized phase 2 trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma [abstract]. J Clin Oncol. 2007;25(suppl):241s. Abstract 5025.
6. Motzer RJ, Rini, BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
7. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2007;179:81-86.
8. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
9. Rini BI, George DJ, Michaelson MD, et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract]. Ann Oncol. 2006;17:144s. Abstract 438O.
10. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol. 2007;25(suppl):244s. Abstract 5038.
11. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res. 2007;13:5670-5674.
12. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122-127
13. Motzer RJ, Escudier B, Oudard S, et al. Efficiency of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008;372:449-456.